Cover Image
市場調查報告書

胰臟外分泌不足:全球臨床實驗檢討

Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 244190
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
胰臟外分泌不足:全球臨床實驗檢討 Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016
出版日期: 2016年11月30日 內容資訊: 英文 77 Pages
簡介

本報告提供胰臟外分泌不足相關之臨床研究最新趨勢分析,提供您疾病·治療方法概要,及G7·E7各國的臨床實驗狀況,各地區、Phase、階段別進行狀況,有潛力的贊助商,各企業及研究機關的研究進行狀況,並彙整有潛力的藥劑比較等資訊。

簡介

  • 胰臟外分泌不足
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 主要國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:胰臟外分泌不足臨床實驗數量上消化管疾病臨床實驗數量所佔的比例

Phase別臨床實驗數量:G7各國

G7各國的臨床實驗數量:Phase別

E7各國的臨床實驗數量:胰臟外分泌不足臨床實驗數量上消化管疾病臨床實驗數量所佔的比例

Phase別臨床實驗數量:E7各國

E7各國的臨床實驗數量:Phase別

Phase別臨床實驗數量

  • Phase別的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

未完成的臨床實驗

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 胰臟外分泌不足治療藥

有潛力的藥劑

臨床實驗簡介

  • 有代表性的企業臨床實驗概要
    • Abbott Laboratories
    • Forest Laboratories, Inc.
    • Digestive Care, Inc.
    • DATAMAP GmbH
    • Parexel International Corporation
    • Anthera Pharmaceuticals, Inc.
    • LAL Clinica Pesquisa e Desenvolvimento Ltda
    • Johnson & Johnson
    • Axcan Pharma Inc.
    • AbbVie Inc.
  • 有代表性的研究機關/醫院臨床實驗概要
    • Fundacion para la Investigacion en Enfermedades Del Aparato Digestivo
    • The Foundation for Liver Research
    • University of Pennsylvania
    • Azienda Ospedaliera Universitaria Integrata Verona
    • Calvary Mater Newcastle
    • Columbia University
    • Seattle Children's Hospital
    • Sheffield Teaching Hospitals NHS Foundation Trust
    • Texas A&M University
    • 東京大學

5大臨床實驗簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3924CTIDB

GlobalData's clinical trial report, "Exocrine Pancreatic Insufficiency Global Clinical Trials Review, H2, 2016" provides an overview of Exocrine Pancreatic Insufficiency clinical trials scenario. This report provides top line data relating to the clinical trials on Exocrine Pancreatic Insufficiency. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials 29
  • Prominent Drugs 31
  • Latest Clinical Trials News on Exocrine Pancreatic Insufficiency 32
  • Nov 17, 2016: AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients 32
  • Clinical Trial Profile Snapshots 33

Appendix 74

  • Abbreviations 74
  • Definitions 74
  • Research Methodology 75
  • Secondary Research 75
  • About GlobalData 76
  • Contact Us 76
  • Disclaimer 76
  • Source 77

List of Tables

List of Tables

  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 10
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
  • Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 16
  • Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
  • Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
  • Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 19
  • Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
  • Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Phase, 2016* 22
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
  • Exocrine Pancreatic Insufficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31

List of Figures

List of Figures

  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 10
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13
  • Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
  • Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17
  • Exocrine Pancreatic Insufficiency Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18
  • Proportion of Exocrine Pancreatic Insufficiency to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 19
  • Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20
  • Exocrine Pancreatic Insufficiency Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23
  • Exocrine Pancreatic Insufficiency Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26
  • Exocrine Pancreatic Insufficiency Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
  • Exocrine Pancreatic Insufficiency Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
  • GlobalData Methodology 75
Back to Top